title: Optimal Outcomes in Young Class 3 Patients With Thalassemia Undergoing HLA-Identical Sibling Bone Marrow Transplantation.
abstract: BACKGROUND
  Bone marrow transplantation (BMT) for class 3 patients with thalassemia is challenging due to high rates of graft rejection and transplant-related mortality. Since the first studies of BMT in the late 1980s, a number of conditioning regimens have been designed to improve outcomes, but with suboptimal results. Here we report the outcome of transplantation in class 3 patients using a modified protocol.
  
  
  METHODS
  Sixty-three patients between 5 and 16.7 years of age with class 3 thalassemia received HLA-matched sibling BMT following either the original protocol (26 patients) or the modified protocol (37 patients). Both regimens comprised preconditioning cytoreduction with hydroxyurea and azathioprine starting at -45 days pretransplant, and fludarabine from days -16 to -12. Conditioning was performed with busulfan and cyclophosphamide (original protocol) or with busulfan, thiotepa, and cyclophosphamide (modified protocol).
  
  
  RESULTS
  The 2 groups showed similar patient demographics. At day 0, the degree of cytoreduction (lymphopenia, neuthropenia, and thrombocytopenia) achieved by the modified protocol was greater than the original protocol. The incidence of graft failure/rejection was significantly higher in the original group (15%; 95% confidence interval [95% CI], 5-32%) compared with the modified group (0%) (P = 0.014). The respective 5-year thalassemia-free survival rates were 73% (95% CI, 51-86%) and 92% (95% CI, 77-97%) (P = 0.047). Both groups showed similar incidences of grades II to IV acute graft-versus host disease. Modified protocol did not increase nonhematological toxicity or infectious complications.
  
  
  CONCLUSIONS
  The modified treatment protocol effectively and safely prevented graft failure/rejection and significantly increased thalassemia-free survival of class 3 patients with thalassemia.
authors.affiliation: 1 International Center for Transplantation in Thalassemia and Sickle Cell Anemia, Mediterranean Institute of Hematology, Policlinico Tor Vergata, Rome, Italy.
authors.forename: Javid
authors.initials: J
authors.lastname: Gaziev
authors.forename: Antonella
authors.initials: A
authors.lastname: Isgrò
authors.forename: Pietro
authors.initials: P
authors.lastname: Sodani
authors.forename: Marco
authors.initials: M
authors.lastname: Marziali
authors.forename: Katia
authors.initials: K
authors.lastname: Paciaroni
authors.forename: Cristiano
authors.initials: C
authors.lastname: Gallucci
authors.forename: Gioia
authors.initials: G
authors.lastname: De Angelis
authors.forename: Marco
authors.initials: M
authors.lastname: Andreani
authors.forename: Manuela
authors.initials: M
authors.lastname: Testi
authors.forename: Cecilia
authors.initials: C
authors.lastname: Alfieri
authors.forename: Michela
authors.initials: M
authors.lastname: Ribersani
authors.forename: Tiziana
authors.initials: T
authors.lastname: Galluccio
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Battarra
authors.forename: Aldo
authors.initials: A
authors.lastname: Morrone
authors.forename: Guido
authors.initials: G
authors.lastname: Lucarelli
mesh_terms: D000293:Adolescent; D000367:Age Factors; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology*; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D015994:Incidence; D053208:Kaplan-Meier Estimate; D019520:Living Donors; D008297:Male; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012307:Risk Factors; D012384:Rome / Q000453:epidemiology; D035781:Siblings; D013789:Thalassemia / Q000175:diagnosis / Q000235:genetics / Q000276:immunology / Q000601:surgery*; D013997:Time Factors; D019172:Transplantation Conditioning; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens; D007166:Immunosuppressive Agents